ResMed Stock Price Target Rockets to $227.57 - Here's the Analysts' Verdict
In the past three months, 7 analysts have released ratings for ResMed (NYSE:RMD), presenting a wide array of perspectives from bullish to bearish. This diverse set of opinions indicates that the analysts have varying views on the company's potential performance in the future.
According to a recent report, the total ratings can be broken down into the following categories: Bullish - 1, Somewhat Bullish - 2, Indifferent - 3, Somewhat Bearish - 1, and Bearish - 0. In the last 30 days, there have been no changes to the ratings, with the same numbers as the previous month.
However, in the 1-month-ago period, the ratings were different, with 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 1 Somewhat Bearish, and 2 Bearish ratings. In the 2-month-ago period, the breakdown was 1 Bullish, 1 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, and 3 Bearish ratings. Lastly, in the 3-month-ago period, there were 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 1 Somewhat Bearish, and 0 Bearish ratings.
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $227.57, accompanied by a high estimate of $280.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.68% from the previous average price target of $219.50.
Expert Insights
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joe Vruwink | Baird | Announces | Outperform | $280.00 | - |
| Mike Polark | Wolfe Research | Announces | Underperform | $180.00 | - |
| Mike Matson | Needham | Maintains | Hold | $236.00 | - |
| Craig Wong-Pan | RBC Capital | Raises | Sector Perform | $206.00 | $204.00 |
| Brett Fishbin | Keybanc | Raises | Overweight | $251.00 | $238.00 |
| Mike Matson | Needham | Maintains | Buy | $236.00 | $236.00 |
| Craig Wong-Pan | RBC Capital | Raises | Sector Perform | $204.00 | $200.00 |
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. This gives a clear view into the expected performance of ResMed in the future, enabling investors to make informed decisions.